
Intuitive Surgical (ISRG) Stock Forecast & Price Target
Intuitive Surgical (ISRG) Analyst Ratings
Bulls say
Intuitive Surgical has demonstrated strong financial performance with a revenue increase of 25% year-over-year, reaching $2.41 billion, and an 18% growth in da Vinci procedures, indicating robust market demand for its robotic surgery systems. The company benefits from an established global installed base of over 9,500 da Vinci systems, with significant opportunities for expansion in emerging markets and additional procedure growth driven by broadening indications and advancements in instrumentation. Given the company's continued innovation, steady utilization increases, and geographic expansion, there is a strong outlook for sustained revenue and earnings growth in the coming years.
Bears say
The financial analysis of Intuitive Surgical reveals a negative outlook primarily due to disappointing guidance on gross margins and operational expenses, with the company's projected gross margin for FY '25 falling short of analyst models. Additionally, certain segments, such as adjusted bariatrics volumes, experienced a decline year-over-year, indicating potential challenges in sustaining growth and market acceptance for new robotic platforms. External factors, including macroeconomic uncertainty affecting hospital budgets and tariffs on imports, further complicate the company's ability to capitalize on its installed base and drive future revenue growth.
This aggregate rating is based on analysts' research of Intuitive Surgical and is not a guaranteed prediction by Public.com or investment advice.
Intuitive Surgical (ISRG) Analyst Forecast & Price Prediction
Start investing in Intuitive Surgical (ISRG)
Order type
Buy in
Order amount
Est. shares
0 shares